OceanTech Acquisitions "announced that its stockholders have approved an extension of the date by which the Company must consummate a business combination from December 2, 2022 to June 2, 2023 at the special meeting of stockholders held on November 29, 2022. The Extension provides the Company with additional time to complete the previously announced proposed business combination with Majic Wheels Corp., a Wyoming corporation. On November 15, 2022, OceanTech entered into a definitive business combination agreement pursuant to which it would acquire Majic Wheels Corp., a Wyoming corporation (the "Target"). Upon the closing of the business combination, which is expected in the first quarter of 2023, the combined company will be named Majic Corp. Majic Corp. expects to remain listed on Nasdaq under the ticker symbol "MJWL" after the consummation of the Business Combination. "

In a regulatory filing, Live Nation Entertainment director Jimmy Iovine disclosed the purchase of 13,740 common shares of the company on December 1 at a price of $73.28 per share.

Theratechnologies "announced that it has decided to pause the enrollment of patients in its Phase 1 clinical trial of TH1902, the Company's lead investigational peptide drug conjugate for the treatment of sortilin-expressing cancers. The Company plans to submit an amendment to its protocol to the U.S. Food and Drug Administration for approval. Theratechnologies voluntarily made the decision to pause enrollment and revisit the study design after consulting with its investigators. Efficacy results observed thus far were not convincing enough to pursue enrolling patients and did not outweigh the adverse events seen in some patients. As previously reported, these adverse events consist mainly of neuropathy and eye toxicity."

In an interview on CNBC's Mad Money, George Kurtz said customers are embracing Crowdstrike and want to buy more of its products, especially at the enterprise level. Net retention rates are near all-time highs, he noted. Lots of SMB customers are in "wait and see mode" with interest rates rising, Kurtz added. They are putting purchases on hold resulting in "elongated sales cycles."

In a regulatory filing, Ivanhoe Electric executive chairman Robert Friedland disclosed the purchase of 422,767 common shares of the company on November 29 at a price of $9.85 per share.

Y-mAbs Therapeutics announced that the U.S. FDA has issued a complete response letter for the Biologics License Application for the investigational medicine I-omburtamab for the treatment of CNS/leptomeningeal metastasis from neuroblastoma. The letter indicates that the FDA completed the review of the application and determined that it is unable to approve the BLA in its current form. This is consistent with the outcome of the Oncologic Drugs Advisory Committee Meeting in October. The CRL includes a recommendation for meeting with the agency to discuss adequate and well-controlled trial design to demonstrate substantial evidence of effectiveness and a favorable benefit-risk profile. Y-mAbs is assessing the implications of the CRL and its plans for the omburtamab program. "We are disappointed by the CRL but not surprised based on the outcome of the ODAC meeting on October 28. We want to express our gratitude to all the patients, their families, and investigators who have participated in our clinical trials and advocated for the advancement of omburtamab," said Thomas Gad, President, and Interim CEO. "While we evaluate the implications of the CRL for the future of omburtamab, we are excited about refining our focus primarily to drive growth from DANYELZA and validate our SADA platform in the clinic, with the goal of bringing innovative solutions to patients and value to our shareholders.